Form 26AS evidence requires successor-entity accounting verification after business transfer, while invoice-supported related-party advertising expend...
Money-laundering judgment timing requires awaiting the scheduled-offence decision despite continuation of the underlying trial where outcomes directly...
Accredited investor eligibility expands through securities-market exposure, while alternative investment fund disputes require prescribed resolution a...
Page of 4916
Press 'Enter' after typing page number.
41 to 60 of 98302 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
ITAT allowed the assessee's appeal. The Tribunal upheld the...
Appeal allows marketing payments as deductible business expenses under Sec.37; director pay retained; R&D deductible from certificate date under Sec.35(2AB) &D
Contents
Summary
Note
Bookmark
Share
✓ Copied successfully !
Print
Print Options
For full text, please login
Login to TaxTMI
Verification Pending
The Email Id has not been verified. Click on the link we have sent on
ITAT allowed the assessee's appeal. The Tribunal upheld the CIT(A)'s finding that payments of Rs.4,38,72,325 to an associate enterprise for marketing support were business-expedient and deductible under section 37, noting the protracted product approval and production cycle and subsequent procurement from a major OEM as linking expenditure to future commercial benefit. The Tribunal rejected disallowance of directors' remuneration, holding prior acceptance in other years and lack of requisite nexus to turnover did not warrant retrospective disallowance for unreasonableness. Expenditure on research and development was held allowable under section 35(2AB) from the certificate issuance date, not for the entire fiscal year.
ITAT allowed the assessee's appeal. The Tribunal upheld the CIT(A)'s finding that payments of Rs.4,38,72,325 to an associate enterprise for marketing support were business-expedient and deductible under section 37, noting the protracted product approval and production cycle and subsequent procurement from a major OEM as linking expenditure to future commercial benefit. The Tribunal rejected disallowance of directors' remuneration, holding prior acceptance in other years and lack of requisite nexus to turnover did not warrant retrospective disallowance for unreasonableness. Expenditure on research and development was held allowable under section 35(2AB) from the certificate issuance date, not for the entire fiscal year.
Note: It is a system-generated summary and is for quick reference only.